Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dexamethasone
Drug ID BADD_D00623
Description Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions.[L10701] Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone].[A188724] Dexamethasone was granted FDA approval on 30 October 1958.[L10695] In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.[L14318]
Indications and Usage Dexamethasone and [ciprofloxacin] otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa.[L10698] Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions.[L10701] Oral tablets are indicated for the treatment of multiple myeloma.[L10710] An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye.[L10719] Various ophthalmic formulations are indicated for inflammatory conditions of the eye.[L10704,L10707,L10713,L10716,L10722,L10725]
Marketing Status approved; investigational; vet_approved
ATC Code A01AC02; C05AA09; D07AB19; D07XB05; D10AA03; H02AB02; R01AD03; S01BA01; S01CB01; S02BA06; S03BA01
DrugBank ID DB01234
KEGG ID D00292
MeSH ID D003907
PubChem ID 5743
TTD Drug ID D0IT2G
NDC Product Code 80425-0328; 0009-5019; 22552-0039; 38779-0405; 0904-7266; 55154-4901; 63187-561; 67296-1496; 70518-2998; 70868-920; 0054-4183; 0054-8176; 0054-8181; 0054-8183; 0998-0615; 55718-133; 71161-138; 79572-012; 42195-490; 45865-989; 55154-4914; 68788-8223; 70382-204; 71205-012; 42291-155; 50090-0088; 60687-718; 60687-729; 64980-509; 68788-8467; 72189-383; 55289-582; 60219-2044; 67296-0326; 0054-4179; 0054-8179; 0054-8180; 72893-015; 55718-157; 65089-0045; 42195-127; 60219-2043; 63629-7850; 70954-402; 71205-013; 0054-4181; 0054-4182; 0054-4186; 71205-703; 71879-001; 46439-8765; 82298-111; 50090-6151; 61919-827; 63187-383; 63629-4129; 63629-7806; 68788-7267; 69306-111; 69306-114; 70518-3050; 70954-404; 0054-4184; 49452-2465; 0078-0925; 0023-3348; 61919-269; 68071-2744; 68788-8293; 0054-3177; 70954-403; 0054-8175; 71335-2108; 72189-254; 51552-0430; 51927-1081; 52128-170; 42195-721; 43063-266; 48102-051; 50090-0089; 54879-003; 60219-2056; 62135-114; 68788-7142; 70954-401; 0054-8174; 72189-468; 60722-3013; 0121-1814; 42195-121; 42195-149; 42195-221; 47781-914; 47781-916; 55700-961; 69306-112; 55289-903; 63629-3742; 66993-730; 67296-1837; 68071-2321; 0054-4180; 55718-156; 57582-031; 57582-931; 42195-270; 50090-6152; 51407-361
UNII 7S5I7G3JQL
Synonyms Dexamethasone | Methylfluorprednisolone | Hexadecadrol | Decameth | Decaspray | Dexasone | Dexpak | Maxidex | Millicorten | Oradexon | Decaject | Decaject-L.A. | Decaject L.A. | Hexadrol
Chemical Information
Molecular Formula C22H29FO5
CAS Registry Number 50-02-2
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Illogical thinking19.10.03.0120.000145%Not Available
Immune effector cell-associated neurotoxicity syndrome19.13.01.006; 17.13.01.015; 12.03.01.0650.000291%Not Available
Immune thrombocytopenia10.02.01.083; 01.08.01.0130.000581%Not Available
Lens disorder06.08.03.0150.000145%Not Available
Lung opacity22.12.01.0060.000145%Not Available
Malignant mediastinal neoplasm22.09.03.011; 16.19.11.0010.000145%Not Available
Minimal residual disease16.21.01.006; 01.13.01.0060.000145%Not Available
Mixed anxiety and depressive disorder19.15.01.0100.000145%Not Available
Myelosuppression01.03.03.0150.000509%Not Available
Neonatal respiratory distress18.04.10.004; 22.11.02.0150.000145%Not Available
Neuropsychological symptoms19.07.03.010; 17.02.05.0730.000363%Not Available
Plasma cell myeloma refractory16.23.02.008; 01.14.02.0080.000145%Not Available
Postnatal growth restriction18.04.02.0080.000145%Not Available
Pseudoendophthalmitis12.02.02.014; 06.06.07.0060.000145%Not Available
Reaction to excipient10.01.01.0420.000320%Not Available
Renal phospholipidosis20.05.03.027; 14.08.04.0280.000145%Not Available
Renal vascular thrombosis24.01.11.005; 20.01.07.0210.000145%Not Available
Serous retinal detachment06.09.03.0370.000436%Not Available
Splenic artery aneurysm24.02.02.011; 07.15.04.0120.000291%Not Available
Steroid diabetes14.06.01.019; 05.06.01.0190.000436%Not Available
Symmetrical drug-related intertriginous and flexural exanthema23.03.05.012; 10.01.01.0460.000509%Not Available
Symptom recurrence08.01.03.1010.000392%Not Available
Taste disorder07.14.03.004; 17.02.07.029--Not Available
Therapy non-responder08.06.01.0630.003051%Not Available
Therapy partial responder08.06.01.0640.001162%Not Available
The 26th Page    First    Pre   26    Total 26 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene